Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibodies that target the neonatal Fc receptor (FcRn) to modulate immune responses in patients with autoimmune diseases. The company aims to enhance patient quality of life by decreasing disease activity and minimizing the side effects associated with existing treatments.
Funding
$450M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RSFounders
Product
Problem
Many autoimmune diseases are caused by harmful immunoglobulin G (IgG) autoantibodies, leading to complex and variable symptoms that significantly impact patients' quality of life. Traditional treatments often involve broad-spectrum immunosuppressive agents that can have significant side effects and may not be tailored to the individual's disease stage or severity.
Solution
Immunovant is developing novel, fully human monoclonal antibodies that target the neonatal Fc receptor (FcRn) to reduce levels of IgG autoantibodies, addressing the root cause of many autoimmune diseases. Their investigational products, IMVT-1402 and batoclimab, are designed to offer a more targeted approach than traditional immunosuppressants, potentially minimizing side effects. These therapies are administered via subcutaneous injection, allowing for dosing that can be tailored based on disease stage and severity, providing a personalized treatment strategy for patients with IgG-mediated autoimmune disorders. By modulating the FcRn pathway, Immunovant aims to provide targeted therapies that can improve the lives of individuals suffering from a range of autoimmune conditions.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases such as Myasthenia Gravis, Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, Rheumatoid Arthritis, Sjogren’s Disease, and Cutaneous Lupus Erythematosus.
Features
- Fully human monoclonal antibodies targeting FcRn
- Subcutaneous injection administration for patient convenience
- Potential for tailored dosing based on disease stage and severity
- IMVT-1402: Investigational product in development for Sjogren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE)
- Batoclimab: Investigational product in Phase 3 trials for Myasthenia Gravis (MG) and Thyroid Eye Disease (TED)
- Batoclimab: Investigational product in Phase 2 trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Designed to reduce harmful IgG autoantibodies, addressing the underlying cause of autoimmune diseases